Achillion achieved threshold enrollment in the Phase 2 trials of ACH-4471 for patients with C3 glomerulopathy or C3G, a devastating disease affecting the kidney for which there is no approved therapy. ACH-4471 will be evaluated in the six-month trial with 11 patients and the 12-month open-label trial with 12 patients. The company expects to present data from these two Phase 2 trials, along with real-world C3G data, to the FDA in Q4. The objective of the six and 12-month proof-of-concept trials is to evaluate the safety and efficacy of ACH-4471 in patients diagnosed with C3G. The measures being evaluated include changes in clinical manifestations of C3G including proteinuria and estimated glomerular filtration rate at the end of the treatment period and changes in kidney biopsy from baseline.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.